144: Filer Information

Filer CIK

0001384243

Filer CCC

XXXXXXXX

Is this a LIVE or TEST Filing?

LIVE

TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer

Kiniksa Pharmaceuticals International, plc

SEC File Number

001-38492

Address of Issuer

105 PICCADILLY, SECOND FLOOR
LONDON
UNITED KINGDOM
W1J 7NJ

Phone

7814319100

Name of Person for Whose Account the Securities are To Be Sold

Quart Barry D

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Director

144: Securities Information

Title of the Class of Securities To Be Sold

Name and Address of the Broker

Number of Shares or Other Units To Be Sold

Aggregate Market Value

Number of Shares or Other Units Outstanding

Approximate Date of Sale

Name the Securities Exchange

Class A ordinary shares

Charles Schwab & Co., Inc.
3000 Schwab Way
Westlake � TX � 76262

20000

1000000.00

45900637

04/06/2026

NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class

Date you Acquired

Nature of Acquisition Transaction

Name of Person from Whom Acquired

Is this a Gift?

Date Donor Acquired

Amount of Securities Acquired

Date of Payment

Nature of Payment *

Class A ordinary shares

04/06/2026

Employee Stock Option Exercise - see remarks

Kiniksa Pharmaceuticals, Ltd.

20000

04/06/2026

Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller

Title of Securities Sold

Date of Sale

Amount of Securities Sold

Gross Proceeds

Barry D Quart
105 PICCADILLY, SECOND FLOOR
LONDON � X0 � W1J 7NJ

Kiniksa Pharmaceuticals International, plc

02/02/2026

830

37354.00

Barry D Quart
105 PICCADILLY, SECOND FLOOR
LONDON � X0 � W1J 7NJ

Kiniksa Pharmaceuticals International, plc

02/03/2026

12528

567136.00

Barry D Quart
105 PICCADILLY, SECOND FLOOR
LONDON � X0 � W1J 7NJ

Kiniksa Pharmaceuticals International, plc

02/04/2026

2602

117138.00

Barry D Quart
105 PICCADILLY, SECOND FLOOR
LONDON � X0 � W1J 7NJ

Kiniksa Pharmaceuticals International, plc

02/10/2026

110

4950.00

Barry D Quart
105 PICCADILLY, SECOND FLOOR
LONDON � X0 � W1J 7NJ

Kiniksa Pharmaceuticals International, plc

02/12/2026

2690

121050.00

144: Remarks and Signature

Remarks

The shares on this filing may be sold over various dates.

Date of Notice

04/06/2026

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

09/11/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Barry D Quart

144: Filer Information

Submission Contact Information

144: Issuer Information

144: Securities Information

144: Securities To Be Sold

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

SEC Form 144 filed by Kiniksa Pharmaceuticals International plc